In Brief: Hi-Tech Pharmacal, OTC firm warned on water tests, John Taylor to leave FDA, NAD and ASA review claims
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal profits plummet; FDA warns OTC firm about GMPs; John Taylor to leave FDA; NAD refers claims for Vysera-CLS to FTC; Circulation Patch It claims lack support – ASA; and U.K. liquid OTC recalls.
You may also be interested in...
Class Action Continues Against Zantrex-3 Maker After Rejected Settlement
The ruling in US District Court for the Eastern New York District notes a Supreme Court decision in January in a separate case that also focused on settlement offers rejected by plaintiffs in civil litigation, a question on which US appellate courts have differed.
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”